Could a simple antibody test predict severe COVID-19?
NCT ID NCT05242159
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study aims to find out how common anti-annexin A2 antibodies are in people hospitalized with COVID-19 and whether these antibodies are linked to lung damage or blood clots. Researchers will test blood samples from 300 adult patients at one hospital. The goal is to see if these antibodies can serve as a marker for severe disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHU Amiens
RECRUITINGAmiens, 80054, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Five years on: how does long COVID evolve?
- Can a targeted pill tame severe COVID-19?
- Can an organic compound tame COVID-19 in High-Risk patients?
- Could exercise retrain the heart in long COVID?
- Can a new drug shield lungs from COVID-19's worst damage?
- Can paxlovid hold the line against severe COVID-19 outside the lab?